The GH Optimisation Stack: CJC-1295 + Ipamorelin

Research disclaimer: These compounds are sold for research purposes only and are not intended for human consumption.

Evidence Tier for This Combination

Human clinical data exists for both compounds individually. The combination is well-established in clinical research. Phase II trial data for CJC-1295; human efficacy and safety studies for Ipamorelin.

This is among the better-evidenced stacks in the peptide literature. Both compounds have been through structured human trials. The combination rationale is based on a dual-receptor mechanism that has been studied and documented in clinical settings.

Why These Two Work Together

Growth hormone release from the pituitary is regulated by two antagonistic signals: GHRH (growth hormone-releasing hormone) stimulates release, and somatostatin inhibits it. Natural GH secretion occurs in pulses — primarily during slow-wave sleep — when GHRH surges and somatostatin is suppressed.

CJC-1295 and Ipamorelin hit two different receptors in this system simultaneously, producing a GH pulse larger than either compound alone.

CJC-1295 → GHRH Receptor

CJC-1295 is a modified analog of GHRH(1-29) with a Drug Affinity Complex (DAC) that binds to albumin, extending its half-life from approximately 30 minutes (native GHRH) to 6–8 days. It acts on the GHRH receptor on pituitary somatotrophs, stimulating GH synthesis and release.

The no-DAC version (Mod-GRF 1-29) has a short half-life (~30 minutes) and produces a sharper, more pulse-like GH release. Most pre-sleep protocols now use Mod-GRF 1-29 (no-DAC) rather than the DAC version for this reason — it more closely mimics the natural GH pulse rather than producing a sustained elevation.

Ipamorelin → Ghrelin Receptor

Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist. It stimulates GH release through a completely different receptor pathway than CJC-1295, and — critically — does so without significantly raising cortisol or prolactin. Earlier GH secretagogues (GHRP-2, GHRP-6) produced GH release but also elevated cortisol, which partially offsets body composition benefits and causes other problems. Ipamorelin’s selectivity makes it the preferred secretagogue for most research protocols.

The Synergy

GHRH-receptor agonism (CJC-1295) and ghrelin-receptor agonism (Ipamorelin) work through different intracellular pathways in pituitary somatotrophs. When activated simultaneously, they produce a superadditive GH pulse — larger than the sum of their individual effects — because cAMP signalling (GHRH pathway) and calcium mobilisation (ghrelin pathway) converge on the same secretory machinery. This is one of the few peptide combinations where true mechanistic synergy (not just additive benefit) has been demonstrated.

Timing Protocol

GH is secreted in pulses, primarily during the first 2–3 hours of sleep. The protocol is designed to augment this natural pulse, not to produce flat GH elevation throughout the day.

Standard pre-sleep protocol:

Important: Do not eat within 2–3 hours before the injection. Elevated insulin from food significantly blunts GH release. This is not optional — it is a primary variable that determines whether the protocol produces meaningful GH elevation.

DAC version alternative: If using CJC-1295 with DAC (the long-acting version), it is typically injected 1–2x per week at 1–2 mg, with Ipamorelin used daily before sleep. This maintains a steady GHRH background with daily Ipamorelin pulses on top. Most protocols have moved toward no-DAC for a more physiological pattern.

Dosing Table

Cycle length: Most protocols run 8–12 weeks, then a break of 4+ weeks. Continuous use risks receptor desensitisation and possible downregulation of endogenous GH release, though this has not been well-characterised in the literature.

What the Evidence Supports

Body composition: Both compounds have been studied for effects on lean mass and fat mass. The effects are real but modest — these compounds raise GH and IGF-1 toward the upper end of normal range, not to supraphysiological levels. The body composition changes are slower and smaller than exogenous GH administration, which is the trade-off for using a secretagogue approach.

Sleep quality: This is a consistently reported and mechanistically supported benefit. GH secretion and slow-wave sleep are tightly coupled. Augmenting the GH pulse can improve sleep architecture. Multiple users of Ipamorelin report improved sleep quality as the most subjectively noticeable effect.

Recovery: Elevated GH and IGF-1 support protein synthesis and tissue repair. This is the basis for using this stack in combination with a repair protocol.

What it is not: This is not exogenous GH. It works by stimulating the pituitary to produce more of what it already makes. The ceiling is set by pituitary capacity, which declines with age. In a 25-year-old with robust pituitary function, the stack may produce less absolute GH elevation than in a 45-year-old whose baseline is significantly suppressed.

What to Expect Realistically

Weeks 1–2: Sleep quality improvement is often the first reported effect. Better sleep depth, potentially more vivid dreams (a GH-related effect).

Weeks 3–6: Some researchers report changes in body composition — mild reduction in subcutaneous fat and modest increase in lean mass recovery from training. These changes are subtle and require consistent protocol adherence (especially the fasted state before injection).

What will not happen: Dramatic muscle gain, rapid fat loss, or effects comparable to exogenous HGH. The secretagogue approach optimises endogenous production within biological limits.

Summary

CJC-1295 + Ipamorelin is one of the most mechanistically well-understood combinations in research peptides, built on dual-receptor activation of the GH-secretory axis with documented synergy and meaningful human trial data. The trade-off versus exogenous GH is reduced potency in exchange for a more physiological mechanism and lower regulatory barrier. For researchers interested in GH axis optimisation without supraphysiological exposure, this is the evidence-backed approach.

See also: CJC-1295 data page · Ipamorelin data page